Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Calcium,Magnesium,Zinc
Therapeutic Area : Nutrition and Weight Loss
Study Phase : Approved FDF
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Torrent Pharma launches nutrition supplement powder Shelcal Total
Details : Shelcal Total is a scientifically formulated with vitamins and minerals as an adult nutrition supplement powder.
Product Name : Shecal Total
Product Type : Vitamins/Minerals/Inorganic Salts
Upfront Cash : Inapplicable
July 23, 2025
Lead Product(s) : Calcium,Magnesium,Zinc
Therapeutic Area : Nutrition and Weight Loss
Highest Development Status : Approved FDF
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Calcium
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
AUR103 Calcium Safety, PK/PD & Efficacy In HER2+ Advanced Gastric/GEJ Adenocarcinoma
Details : Calcium is a Vitamins/Minerals/Inorganic Salts drug candidate, which is currently being evaluated in Phase I/ Phase II clinical studies for the treatment of Stomach Neoplasms.
Product Name : Undisclosed
Product Type : Vitamins/Minerals/Inorganic Salts
Upfront Cash : Inapplicable
June 26, 2025
Lead Product(s) : Calcium
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : SFA-002,Calcium,Magnesium
Therapeutic Area : Dermatology
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
SFA Thera Announces Completion of Enrollment in Phase 1b Trial of SFA-002 for Psoriasis
Details : SFA002 is an oral drug for the treatment of mild-moderate psoriasis. It has a potential multi-target and disease-modifying therapeutic that has demonstrated efficacy, safety and durability.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
May 30, 2024
Lead Product(s) : SFA-002,Calcium,Magnesium
Therapeutic Area : Dermatology
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Vitamin D,Calcium,Potassium
Therapeutic Area : Immunology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
BioAdaptives, Inc. Commences Development of a New Supplement for Womens Health
Details : PluriPain-PMS, an advanced, all natural anti-inflammatory and mood-enhancing Women’s Health formula to combat specific symptoms associated with the menstrual cycle.
Product Name : PluriPain-PMS
Product Type : Vitamins/Minerals/Inorganic Salts
Upfront Cash : Inapplicable
May 10, 2023
Lead Product(s) : Vitamin D,Calcium,Potassium
Therapeutic Area : Immunology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Glycine,Calcium
Therapeutic Area : Otolaryngology (Ear, Nose, Throat)
Study Phase : Approved FDF
Sponsor : Cipla
Deal Size : $48.6 million
Deal Type : Acquisition
Cipla to Acquire South Africa-based Actor Pharma
Details : Through the acquisition, Cipla strengthen its wellness portfolio by gaining access of Nozohaem (glycine and Calcium), a unique, gel treatment for nosebleeds that stops the bleeding in moments.
Product Name : Nozohaem
Product Type : Dietary Supplement
Upfront Cash : $48.6 million
May 09, 2023
Lead Product(s) : Glycine,Calcium
Therapeutic Area : Otolaryngology (Ear, Nose, Throat)
Highest Development Status : Approved FDF
Sponsor : Cipla
Deal Size : $48.6 million
Deal Type : Acquisition
Lead Product(s) : Calcium
Therapeutic Area : Musculoskeletal
Study Phase : Undisclosed
Sponsor : Tine | The Research Council of Norway
Deal Size : Inapplicable
Deal Type : Inapplicable
Profylactic Treatment for Patients in Risk Osteoporosis
Details : Undisclosed
Product Name : Undisclosed
Product Type : Vitamins/Minerals/Inorganic Salts
Upfront Cash : Inapplicable
March 28, 2023
Lead Product(s) : Calcium
Therapeutic Area : Musculoskeletal
Highest Development Status : Undisclosed
Sponsor : Tine | The Research Council of Norway
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Calcium
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Pre-diltiazem, Calcium Versus Placebo for Atrial Fibrillation With Rapid Ventricular Response
Details : Undisclosed
Product Name : Undisclosed
Product Type : Vitamins/Minerals/Inorganic Salts
Upfront Cash : Inapplicable
January 20, 2023
Lead Product(s) : Calcium
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Calcium
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Study Phase : Phase III
Sponsor : Aga Khan University | Institut Africain de Sante Publique | Zvitambo Institute for Maternal and Child Health Research | Christiana Care Health Services | Columbia University
Deal Size : Inapplicable
Deal Type : Inapplicable
Calcium Aspirin Multiple Micronutrients (CAMMS) to Reduce Preterm Birth
Details : Undisclosed
Product Name : Undisclosed
Product Type : Vitamins/Minerals/Inorganic Salts
Upfront Cash : Inapplicable
November 14, 2022
Lead Product(s) : Calcium
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Highest Development Status : Phase III
Sponsor : Aga Khan University | Institut Africain de Sante Publique | Zvitambo Institute for Maternal and Child Health Research | Christiana Care Health Services | Columbia University
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Calcium
Therapeutic Area : Trauma (Emergency, Injury, Surgery)
Study Phase : Phase II
Sponsor : Miami VA Healthcare System | VA Salt Lake City Health Care System
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Vitamins/Minerals/Inorganic Salts
Upfront Cash : Inapplicable
May 10, 2022
Lead Product(s) : Calcium
Therapeutic Area : Trauma (Emergency, Injury, Surgery)
Highest Development Status : Phase II
Sponsor : Miami VA Healthcare System | VA Salt Lake City Health Care System
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Calcium,Magnesium,Potassium
Therapeutic Area : Sleep
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Jazz Pharmaceuticals to Present New Data at SLEEP 2022 Reinforcing Leadership in Sleep Medicine
Details : Xywav (Calcium) is a lower-sodium oxybate approved by FDA for the treatment of cataplexy or excessive daytime sleepiness in patients 7 years of age and older with narcolepsy and for the treatment of idiopathic hypersomnia in adults.
Product Name : Xywav
Product Type : Vitamins/Minerals/Inorganic Salts
Upfront Cash : Inapplicable
January 06, 2022
Lead Product(s) : Calcium,Magnesium,Potassium
Therapeutic Area : Sleep
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable